FeesSafety
Pluang+

Great Elm Capital reports Q3 2026 results with $0.17 NII per share and declares 20.2% annual dividend yield.

Company Fundamentals
02 Nov 2026, 23:05 WIB
GlobeNewsWire
View Source
Neutral
Great Elm Capital reports Q3 2026 results with $0.17 NII per share and declares 20.2% annual dividend yield.

Great Elm Capital Corp. announced its Q3 2026 financial results, reporting net investment income of $0.17 per share and a net asset value of $7.40 per share. Despite a challenging credit environment and declines in income and NAV, the company maintained strong liquidity with $6 million in cash and $44 million available on its credit facility. The board declared a $0.25 per share dividend for Q4 2026, equating to a 20.2% annualized yield, and repurchased shares at a 33% discount to NAV, signaling confidence in long-term value. Management emphasized ongoing portfolio optimization and a growing pipeline of private investment opportunities to improve future earnings and shareholder value.

Great Elm Capital Corp.'s Q3 2026 results provide context for readers. For those following Financials, 83 of 142 US stocks on Pluang rose and 59 fell. Notable movers include BN at USD 41.53 with a 5.73% gain and 100% sell order activity, FUTU at USD 103.80 up 5.43% also with 100% sell activity, and SEZL at USD 128.40 down 4.78% with 80% buy activity. This data is as of Nov 03, 2026 04:11 WIB.

More News

Zentalis grants 136,000 stock options to new hires under Nasdaq inducement rule

Zentalis grants 136,000 stock options to new hires under Nasdaq inducement rule

Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...

Company Fundamentals
Neutral
1 hour ago
Dianthus Therapeutics grants stock options to new hires under Nasdaq inducement rule

Dianthus Therapeutics grants stock options to new hires under Nasdaq inducement rule

Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...

Company Fundamentals
Neutral
1 hour ago
Federal Home Loan Bank of Atlanta elects new directors and appoints 2027 Chair and Vice Chair.

Federal Home Loan Bank of Atlanta elects new directors and appoints 2027 Chair and Vice Chair.

The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...

Neutral
3 hours ago
FDA halts Bright Minds' epilepsy trial over toxicity concerns, triggering stock selloff and investor investigation

FDA halts Bright Minds' epilepsy trial over toxicity concerns, triggering stock selloff and investor investigation

The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...

Market News
Bearish
5 hours ago
NVIDIA releases Cosmos recipes for advanced vehicle, robot, and surgical simulations using AI models.

NVIDIA releases Cosmos recipes for advanced vehicle, robot, and surgical simulations using AI models.

NVIDIA has published detailed implementation recipes for its Cosmos world models, enabling developers to create simulations for vehicles, robots, and surgical procedures. These recipes guide model adaptation, testing, and GPU deployment, supporting v...

Protocol Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App